AML treated with the FLAG-Ida induction chemotherapy protocol shows improved overall survival (OS) compared to the “7 + 3” daunorubicin and cytarabine induction regimen, but composite complete remission (CRc) remains relatively low at 57% with the FLAG-Ida induction in newly diagnosed acute myelogenous leukemia (ND-AML) patients [5]. Here, IDUA is linked to acute myeloid leukemia.